TP53 and cancer: A recent study of clonal hematopoiesis in cancer patients treated by radiation, platinum, or topoisomerase II inhibitors found that preferentially selected somatic mutations affect all members of this circuit (ATM, CHEK2, PPM1D, and TP53) and increase the risk of therapy-related myeloid neoplasm development [59].